

VIREXX MEDICAL CORP  
Form 6-K  
May 16, 2007

**FORM 6-K**

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

For the month ended  
May 2007

Commission File Number  
1-32608

**VIREXX MEDICAL CORP.**

(Translation of registrant's name into English)

8223 Roper Road NW, Edmonton, Alberta,  
Canada T6E 6S4

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F  .....

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ..... No  ..

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-  
\_\_\_\_\_

**EXHIBIT LIST**

Exhibit  
99.1 Material Change  
Report

Description  
*(ViRexx announces a change in management and to its  
board of Directors and the appointment of Interim Chief  
Executive Officer and the formation of a special committee  
of the Board)*

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

***VIREXX MEDICAL CORP.***

Date: May 14, 2007

By: */s/ Gary Woerz*

Gary Woerz  
Chief Financial Officer